JP2023011601A5 - - Google Patents

Download PDF

Info

Publication number
JP2023011601A5
JP2023011601A5 JP2022161758A JP2022161758A JP2023011601A5 JP 2023011601 A5 JP2023011601 A5 JP 2023011601A5 JP 2022161758 A JP2022161758 A JP 2022161758A JP 2022161758 A JP2022161758 A JP 2022161758A JP 2023011601 A5 JP2023011601 A5 JP 2023011601A5
Authority
JP
Japan
Prior art keywords
formulation
histidine
polypeptide
seq
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022161758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023011601A (ja
JP7442595B2 (ja
Filing date
Publication date
Priority claimed from JP2019560087A external-priority patent/JP7157082B2/ja
Application filed filed Critical
Publication of JP2023011601A publication Critical patent/JP2023011601A/ja
Publication of JP2023011601A5 publication Critical patent/JP2023011601A5/ja
Application granted granted Critical
Publication of JP7442595B2 publication Critical patent/JP7442595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022161758A 2017-05-03 2022-10-06 ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤 Active JP7442595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500649P 2017-05-03 2017-05-03
US62/500,649 2017-05-03
JP2019560087A JP7157082B2 (ja) 2017-05-03 2018-05-03 ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019560087A Division JP7157082B2 (ja) 2017-05-03 2018-05-03 ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤

Publications (3)

Publication Number Publication Date
JP2023011601A JP2023011601A (ja) 2023-01-24
JP2023011601A5 true JP2023011601A5 (cg-RX-API-DMAC7.html) 2023-07-06
JP7442595B2 JP7442595B2 (ja) 2024-03-04

Family

ID=62223280

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019560087A Active JP7157082B2 (ja) 2017-05-03 2018-05-03 ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤
JP2022161758A Active JP7442595B2 (ja) 2017-05-03 2022-10-06 ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019560087A Active JP7157082B2 (ja) 2017-05-03 2018-05-03 ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤

Country Status (12)

Country Link
US (2) US20200129595A1 (cg-RX-API-DMAC7.html)
EP (1) EP3618809A1 (cg-RX-API-DMAC7.html)
JP (2) JP7157082B2 (cg-RX-API-DMAC7.html)
KR (2) KR102838263B1 (cg-RX-API-DMAC7.html)
CN (1) CN110621302A (cg-RX-API-DMAC7.html)
AU (2) AU2018261154B2 (cg-RX-API-DMAC7.html)
CA (1) CA3062797A1 (cg-RX-API-DMAC7.html)
IL (2) IL270233B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019012506A (cg-RX-API-DMAC7.html)
SG (1) SG11201909709SA (cg-RX-API-DMAC7.html)
TW (1) TWI897843B (cg-RX-API-DMAC7.html)
WO (1) WO2018204617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
TWI897843B (zh) * 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
TW202432577A (zh) * 2023-02-10 2024-08-16 美商拜奧海芬治療學有限公司 投與基於纖連蛋白之支架域蛋白以治療超重、肥胖及相關健康病狀
WO2025177263A1 (en) * 2024-02-25 2025-08-28 Biohaven Therapeutics Ltd. Myostatin-binding proteins

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP2003528632A (ja) 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子(vegf)−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
CA2416219C (en) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20070149458A1 (en) 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
AU2008345424A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
EP2247615B1 (en) * 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
AR071874A1 (es) * 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
WO2011051466A1 (en) * 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
PE20130041A1 (es) * 2010-02-18 2013-01-28 Bristol Myers Squibb Co Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
EP3091028A1 (en) * 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
WO2014015027A1 (en) * 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
TWI897843B (zh) * 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
US11173805B2 (en) * 2018-01-30 2021-11-16 Karma Automotive Llc State-of-charge display system

Similar Documents

Publication Publication Date Title
US10098876B2 (en) Treating sexual desire disorders with flibanserin
KR102664288B1 (ko) 카파 오피오이드 수용체 효능제의 경구 제형
RU2384333C2 (ru) Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин
JP2024160287A5 (cg-RX-API-DMAC7.html)
US20050277629A1 (en) Methods for the treatment of synucleinopathies (Lansbury)
US8759400B2 (en) Histone deacetylase inhibitors for enhancing activity of antifungal agents
CN114727999A (zh) 用于预防hiv的衣壳抑制剂
JP2024156754A5 (cg-RX-API-DMAC7.html)
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
CN108347929A (zh) 用于治疗疱疹病毒诱导的病况的方法和组合物
JP2025163108A5 (cg-RX-API-DMAC7.html)
US20100273868A1 (en) R-Zileuton for Use in Conditions Associated with Increased 5-Lipoxygenase and/or Leukotriene Activity (EG Asthma)
JP2023518066A5 (cg-RX-API-DMAC7.html)
JP2023076632A5 (cg-RX-API-DMAC7.html)
JP7610410B2 (ja) 副甲状腺ホルモンアナログの経口製剤および治療
CN1324607A (zh) 用于指甲和周围组织真菌感染局部治疗的抗真菌剂和溶角蛋白剂的可控释放系统
JP2024522817A5 (cg-RX-API-DMAC7.html)
JP2022028975A5 (cg-RX-API-DMAC7.html)
PE20080233A1 (es) Suspension acuosa estable antiinflamatoria
CO2026000726A2 (es) Una forma farmacéutica sólida de dosificación bucodispersable de safinamida
JP4812225B2 (ja) 生理活性ペプチド含有腸溶性製剤
MX9704079A (es) Liberacion de farmacos antiinflamatorios no esteroides empleando uan goam hidrocoloide en polvo que se obtiene de plantas superiores.
NO321151B1 (no) Anvendelse av 2-amino-6-n-propyl-4,5,6,7-tetrahydrobenzotiazol, dets (-)-enantiomer eller et farmasoytisk akseptabelt salt av disse, for fremstilling av et medikament for behandling av "restless leg"- syndromet hos en pasient som lider eller mistenkes a ha denne tilstand
JP2011084581A (ja) 経鼻投与用医薬組成物
JP2022521266A5 (cg-RX-API-DMAC7.html)